Eliem Therapeutics Inc

NASDAQ:ELYM   3:59:52 PM EDT
2.93
+0.05 (+1.74%)
Regulatory, Other Pre-Announcement

Eliem Therapeutics Provides ETX-810 Program Update

Published: 08/02/2022 11:41 GMT
Eliem Therapeutics Inc (ELYM) - Eliem Therapeutics Provides Etx-810 Program Update.
Eliem Therapeutics - in Phase 2a Trial in Lsrp, Etx-810 Did Not Achieve Statistically Significant Separation From Placebo on Trial's Primary Endpoint.
Eliem Therapeutics - Result is Consistent With Lack of Separation From Placebo Observed in Phase 2a Clinical Trial in Dpnp, As Reported in April 2022.
Eliem Therapeutics Inc - Elected to Discontinue Further Development of Etx-810.
Eliem Therapeutics Inc - With Discontinuation of Etx-810, Anticipates That Its Cash Runway Will Extend Beyond Mid-2024.